Glycated haemoglobin A1c (HbA1c) for detection of diabetes mellitus and impaired fasting glucose in Malawi: a diagnostic accuracy study. by Rathod, Sujit D et al.
Rathod, SD; Crampin, AC; Musicha, C; Kayuni, N; Banda, L; Saul,
J; McLean, E; Branson, K; Jaffar, S; Nyirenda, MJ (2018) Glycated
haemoglobin A¡sub¿1c¡/sub¿ (HbA¡sub¿1c¡/sub¿) for detection of di-
abetes mellitus and impaired fasting glucose in Malawi: a diagnostic
accuracy study. BMJ open, 8 (5). e020972. ISSN 2044-6055 DOI:
https://doi.org/10.1136/bmjopen-2017-020972
Downloaded from: http://researchonline.lshtm.ac.uk/4647697/
DOI: 10.1136/bmjopen-2017-020972
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
1Rathod SD, et al. BMJ Open 2018;8:e020972. doi:10.1136/bmjopen-2017-020972
Open Access 
Glycated haemoglobin A1c (HbA1c) for 
detection of diabetes mellitus and 
impaired fasting glucose in Malawi: a 
diagnostic accuracy study
Sujit D Rathod,1 Amelia C Crampin,2 Crispin Musicha,3 Ndoliwe Kayuni,3 
Louis Banda,3 Jacqueline Saul,2 Estelle McLean,2,3 Keith Branson,2 
Shabbar Jaffar,4 Moffat J Nyirenda2
To cite: Rathod SD, Crampin AC, 
Musicha C, et al.  Glycated 
haemoglobin A1c (HbA1c) for 
detection of diabetes mellitus 
and impaired fasting glucose 
in Malawi: a diagnostic 
accuracy study. BMJ Open 
2018;8:e020972. doi:10.1136/
bmjopen-2017-020972
 ► Prepublication history and 
additional material for this paper 
are available online. To view 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2017- 020972).
Received 5 December 2017
Revised 26 March 2018
Accepted 6 April 2018
1Department of Population 
Health at London School of 
Hygiene and Tropical Medicine, 
London School of Hygiene and 
Tropical Medicine, London, UK
2Department of Infectious 
Disease Epidemiology at London 
School of Hygiene and Tropical 
Medicine, London School of 
Hygiene and Tropical Medicine, 
London, UK
3Malawi Epidemiology and 
Intervention Research Unit, 
Chilumba, Malawi
4Department of International 
Public Health at Liverpool School 
of Tropical Medicine, Liverpool 
School of Tropical Medicine, 
Liverpool, UK
Correspondence to
Dr Sujit D Rathod;  
 sujit. rathod@ lshtm. ac. uk
Research
AbstrACt
Objectives To examine the accuracy of glycated 
haemoglobin A1c (HbA1c) in detecting type 2 diabetes and 
impaired fasting glucose among adults living in Malawi.
Design A diagnostic validation study of HbA1c. Fasting 
plasma glucose (FPG) ≥7.0 mmol/L was the reference 
standard for type 2 diabetes, and FPG between 6.1 and 
6.9 mmol/L as impaired fasting glucose.
Participants 3645 adults (of whom 63% were women) 
recruited from two demographic surveillance study sites 
in urban and rural Malawi. This analysis excluded those 
who had a previous diagnosis of diabetes or had history of 
taking diabetes medication.
results HbA
1c demonstrated excellent validity to detect 
FPG-defined diabetes, with an area under the receiver 
operating characteristic (AUROC) curve of 0.92 (95% CI 
0.90 to 0.94). At HbA
1c ≥6.5% (140 mg/dL), sensitivity 
was 78.7% and specificity was 94.0%. Subgroup AUROCs 
ranged from 0.86 for participants with anaemia to 0.94 
for participants in urban Malawi. There were clinical and 
metabolic differences between participants with true 
diabetes versus false positives when HbA
1c was ≥6.5% 
(140 mg/dL).
Conclusions The findings from this study provide 
justification to use HbA
1c to detect type 2 diabetes. As 
HbA1c testing is substantially less burdensome to patients 
than either FPG testing or oral glucose tolerance testing, 
it represents a useful option for expanding access to 
diabetes care in sub-Saharan Africa.
IntrODuCtIOn 
Over 400 million people live with type 2 
diabetes worldwide, with more than 75% 
of these in low/middle-income countries.1 
While the prevalence of diabetes in sub-Sa-
haran African is lower than in other global 
regions, around 6%–9%,2 3 demographic 
models project that this region will experi-
ence the fastest growth rate in cases over the 
next 20 years.1 Approximately 50%–66% of 
people with diabetes are undiagnosed,1 4 and 
complications are common even after diag-
nosis.5 As barriers to diabetes care become 
surmounted in this region,4 focus must turn 
to improving the accessibility of diagnostics.
The diagnosis of diabetes has tradition-
ally been based on the detection of elevated 
plasma glucose levels, either after fasting 
or 2 hours after an oral glucose tolerance 
test, or, in symptomatic individuals, after a 
random blood glucose check.6 While these 
tests are available in sub-Saharan Africa, 
access to services is limited, travel times and 
clinic waiting times are high and integrity 
of the samples and quality of the measuring 
tools are in most cases uncertain. More reli-
able approaches to circumvent some of these 
challenges are required. Recently, the Amer-
ican Diabetes Association and the WHO have 
recommended using glycated haemoglobin 
A1c (HbA1c) in blood to diagnose diabetes 
mellitus.7 8 HbA1c testing provides significant 
practical advantages over glucose testing as it 
does not fluctuate appreciably and thus can 
be performed at any time of the day. Further, 
HbA1c testing does not require any special 
pretest preparations, such as overnight fasting 
or glucose loading.
There are acknowledged limitations 
when attempting to measure HbA1c levels 
which may be relevant for diagnostics in 
strengths and limitations of this study
 ► Only two studies have assessed the validity of gly-
cated  haemoglobin A1c  to detect type 2 diabetes 
in African-origin populations; this is the first such 
study from Malawi.
 ► We used fasting plasma glucose as the reference 
standard, which is commonly used in clinical prac-
tice and for validation studies.
 ► The results of this study may not be generalisable 
to other populations in sub-Saharan Africa, or those 
with anaemia.
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sub-Saharan Africa.6 8 9 It is unclear whether one can use 
HbA1c to diagnose diabetes for people who have malaria,
6 
haemolytic anaemia,10 11 sickle cell anaemia,12 HIV infec-
tion13 14 or who are of African descent.15 16 Given uncer-
tainty around the validity of HbA1c to diagnose type 2 
diabetes and its precursor, impaired fasting glucose, in 
sub-Saharan Africa, we conducted a diagnostic accuracy 
study in Malawi, and have reported results here.
DesIgn AnD methODs
study setting
This report uses data collected as part of a Malawi 
Epidemiology and Intervention Research Unit survey, 
which aimed to understand the burden and risk factors 
of non-communicable diseases in Malawi,17 where the 
national prevalence of diabetes is estimated to be 5.6%.18 
Community-based cross-sectional surveys were conducted 
in Karonga District (May 2013–April 2016)19 and Lilongwe 
City (June 2013–April 2017).17 Karonga is a rural, low-al-
titude, malaria-endemic district in northern Malawi, and 
Lilongwe is an urban, high-altitude city in central Malawi 
with lower malaria prevalence.
recruitment and data collection
Detailed study procedures have been previously 
reported.17 All adults aged 18 years and above who were 
usually residents in either of the study sites were eligible 
to participate in the parent study. All households were 
approached consecutively, and all residents aged ≥18 
years were recruited. Recruits provided written informed 
consent for each separate study component (ie, stan-
dardised interview, physical measurements and blood 
specimen collection) and could opt out of any compo-
nent. Venipuncture was conducted after a minimum 
8-hour fasting period and whole blood samples were 
collected in sodium fluoride tubes. Tubes were stored on 
ice in an insulated cool box and delivered to the labora-
tory for processing (mean delivery time of 2.6 hours after 
blood collection), and glucose analysis was completed 
within 1 hour after processing. Quantitative determi-
nation of fasting plasma glucose (FPG) (hexokinase 
method) and HbA1c was performed using the Beckman 
Coulter Chemistry Analyzer AU480 system according to 
the manufacturer’s guidelines.
FPG testing was conducted on all participant samples. 
HbA1c testing was conducted on all participants samples 
for which FPG results were greater than 5.6 mmol/L and 
in a 10% random sample of those with FPG lower than 
5.6 mmol/L. The laboratory technician who conducted 
the HbA1c test was blind to the participants’ clinical char-
acteristics and FPG result. Nearly all (87%) of HbA1c tests 
were completed within 24 hours of FPG test. Cut-points 
recommended by WHO were used to define FPG as 
normal (<6.1 mmol/L), impaired fasting glucose (6.1 
to 6.9 mmol/L) or diabetes (≥7.0 mmol/L).20 Cate-
gories of body mass index (BMI) for underweight/
normal (BMI <25 kg/m2), overweight (25≤BMI<30) and 
obese (BMI ≥30) and categories for anaemia (haemo-
globin <12.0 g/dL for women and <13.5 for men) were 
used.
statistical analyses
Participants who reported a past diagnosis of diabetes or 
history of taking diabetes medication were excluded from 
this analysis. First, demographic and clinical variables (ie, 
age, sex, location, BMI, blood pressure, plasma glucose 
and lipid profile and HIV serostatus) were described sepa-
rately for the Karonga and Lilongwe samples. Medians 
and IQRs were reported for the continuous measures, 
as most of these measures were skewed, and proportions 
for categorical measures. Second, distribution of HbA1c 
level was compared by FPG result (<7.0 vs ≥7.0 mmol/L) 
with logistic regression. Third, the validity of HbA1c for 
diagnosing diabetes, using FPG (>7.0 mmol/L) as refer-
ence standard, was assessed by using Somers’ D statistic 
with Harrell’s C transformation to estimate the area 
under the receiver operating characteristics (AUROCs) 
curve and 95% CI. Validity statistics (ie, sensitivity, spec-
ificity and positive and negative likelihood ratios) were 
reported for standardised HbA1c scores which corre-
spond to 1.0, 2.0, 3.0 and 4.0 SD above the sample’s 
mean HbA1c score, at an ‘optimal’ value identified by 
Youden’s J statistic (where the sum of the sensitivity and 
specificity reaches its maximum),21 and at 6.5% (140 mg/
dL), which is the value recommended by several diabetes 
associations. The standardised values were generated 
using the distribution of HbA1c scores from the diabe-
tes-negative participants with HbA1c test results (ie, all 
participants with FPG ≥5.6 mmol/L and a 10% subsample 
of participants with plasma glucose <5.6) such that the 
subsampled participants were upweighted 10-fold before 
generating the distribution. Fourth, to consider the 
validity of HbA1c to detect diabetes across subgroups, the 
ROC analysis was stratified by site, sex, BMI and haemo-
globin level. Within each stratum, the sensitivity, spec-
ificity and positive and negative likelihood ratio when 
using HbA1c ≥6.5% (140 mg/dL) as a cut-off score were 
reported. Fifth, the AUROC and 95% CI for detecting 
impaired fasting glucose (FPG ≥6.1 mmol/L) with HbA1c 
were estimated among those who did not have diabetes 
(FPG <7.0 mmol/L). Finally, the clinical characteristics 
were described for the subsets of participants who had 
FPG-defined diabetes, and for true/false-positive partic-
ipants with HbA1c ≥6.5% (140 mg/dL). Again, medians 
and IQRs were reported for continuous measures and 
proportions for categorical measures. The analysis was 
conducted using Stata SE V.14.2 (StataCorp, College 
Station, Texas, USA) (See Stata code in online supple-
mentary material) with complete case analysis. Aside 
count figures, the statistical results were weighted by the 
inverse probability of receiving the HbA1c test.
ethical approval
The study protocol was reviewed and approved. Partic-
ipants identified as having diabetes were referred to 
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chronic care clinics established in conjunction with the 
Malawi Ministry of Health, where they initiated manage-
ment per national treatment guidelines.
Patient and public involvement
The Karonga and Lilongwe population platforms’ 
research priorities have reflected the Malawi National 
Health Research Agenda, and operate through a long-
standing research partnership with the Malawi National 
Ministry of Health and Malawi College of Medicine. The 
design and aims of these platforms were developed in 
a stakeholders’ meeting in Lilongwe, the capital city of 
Malawi, attended by policy makers, policy implementers 
and researchers. The designs of the platforms were influ-
enced by staff working closely with the communities 
and engaging through community meetings. Prior to 
launching new substudies, the research team conducts 
community sensitisation events with dancing, dramas 
and question and answer sessions. In Karonga, village 
elders and other responsible community members 
were responsible for enumerating households, and for 
reporting household vital events and household migra-
tions. In Lilongwe, block leaders were involved in sensiti-
sation and communication with the community prior to 
enumeration by research staff. Preliminary results from 
this study have been disseminated at a conference held at 
the University of Malawi College of Medicine, and presen-
tations for lay audiences, such as for the participating 
communities, are being prepared.
results
As shown in the Standards for Reporting of Diagnostic 
Accuracy Studies (STARD) flow diagram (figure 1), 
30 574 adults consented to the interview and clinical 
Figure 1 Standards for Reporting of Diagnostic Accuracy Studies (STARD) diagram. FPG, fasting plasma glucose ; HbA1c, 
glycated haemoglobin   A1c.
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examination in the parent study, of whom 27 846 also 
provided consent for blood specimen collection, as was 
required for this substudy. No participant experienced a 
severe adverse event due to the specimen collection. This 
analysis includes the 3645 participants (1613 in Karonga 
and 2032 in Lilongwe) who had both FPG and HbA1c 
levels measured, and who did not report prior diagnosis 
of diabetes by a medical professional.
Demographic and clinical characteristics
The demographic and clinical characteristics of analysis 
participants are reported in table 1.
For the 3645 participants, the median age was 33 years 
(IQR 24–44) and 63% were women. The median HbA1c 
level was 5.3% (IQR 4.9–5.7) and 7.3% had HbA1c level 
of 6.5% (140 mg/dL) or higher. The median FPG level 
was 4.7 mmol/L (IQR 4.3–5.0); 1.8% of participants had 
an FPG level consistent with impaired fasting glucose and 
another 1.7% with diabetes.
Diagnostic validity of hbA1c
For every percentage unit increase in HbA1c score, there 
was an almost threefold increase in the odds of having 
FPG-defined diabetes (OR 2.80, 95% CI 2.21 to 3.53, 
R2 0.371, Wald Χ2(1) 75.5, p<0.001). Further, HbA1c 
demonstrated excellent validity to detect for FPG-de-
fined diabetes, with an AUROC of 0.92 (95% CI 0.90 to 
0.94). Validity statistics are presented for a range of HbA1c 
cut-points in table 2.
An HbA1c value of 6.0% corresponded to 1.0 SD above 
the mean in the diabetes-negative sample’s distribution 
of HbA1c scores; at this cut-point, 84.4% of people with 
diabetes would test positive (sensitivity) and 86.9% of 
people without diabetes would test negative (specificity). 
At the commonly recommended HbA1c threshold of 6.5% 
(140 mg/dL), sensitivity was 78.7% and specificity was 
94.0%. Youden’s J was at an HbA1c value of 6.6%, where 
sensitivity was 78.3% and specificity was 94.6%. Stra-
tum-specific AUROCs (table 3) ranged from a minimum 
of 0.86 for participants with anaemia to a maximum of 
0.94 for participants in Lilongwe. With HbA1c ≥6.5% (140 
mg/dL), participants with anaemia had 61.5% sensi-
tivity, 96.4% specificity and a positive likelihood ratio of 
17.4, and the corresponding figures for participants in 
Lilongwe were 70.2%, 95.4% and 15.2.
Among participants who did not have FPG-defined 
diabetes, the HbA1c score had average validity to detect 
Table 1 Demographic and clinical characteristics of participants in Karonga and Lilongwe, Malawi, 2013–2017
Total
(n=3645)
Median and IQR or n and %
Karonga
(n=1613)
Median and IQR, or n and %
Lilongwe (n=2032)
Median and IQR, or n and %
Age, years 33 (25–44) 34 (26–47) 31 (24–41)
Female sex, % 63.0 58.3 67.2
Body mass index (BMI), kg/m2 22.6 (20.5–26.0) 21.8 (20.0–23.8) 23.8 (21.2–28.0)
  Normal BMI, % 61.1 81.9 57.8
  Overweight BMI, % 20.4 13.8 26.1
  Obese BMI, % 10.5 4.3 16.0
Systolic blood pressure, mm Hg 119 (111–129.5) 117.5 (110–127.5) 121 (112.5–131)
Diastolic blood pressure, mm Hg 72.5 (66.5–79.5) 72 (66–78) 73 (67–80.5)
Total cholesterol, mmol/L 3.8 (3.3–4.6) 3.8 (3.2–4.5) 3.9 (3.3–4.6)
Triglycerides, mmol/L 0.80 (0.58–1.14) 0.81 (0.58–1.12) 0.80 (0.59–1.18)
High-density lipoprotein, mmol/L 1.12 (0.94–1.31) 1.09 (0.91–1.28) 1.15 (0.98–1.34)
Low-density lipoprotein, mmol/L 2.53 (2.06–3.10) 2.44 (2.00–2.96) 2.62 (2.14–3.22)
Haemoglobin, g/dL 13.7 (12.6–14.9) 13.7 (12.6–15.0) 13.7 (12.6–14.9)
  Normal haemoglobin, % 82.0 81.1 82.7
  Anaemia, % 18.0 18.9 17.3
HIV positive, % 8.5 7.8 9.1
HbA1c % 5.3 (4.9–5.7) 5.1 (4.7–5.5) 5.4 (5.1–5.8)
HbA1c ≥ 6.5% (140 mg/dL), % 7.3 5.6 8.8
Fasting plasma glucose (FPG), 
mmol/L 4.7 (4.3–5.0) 4.7 (4.3–5.0) 4.7 (4.4–5.1)
FPG 6.1–7.0 mmol/L, % 1.8 1.7 1.9
FPG ≥7.0 mmol/L , % 1.7 1.3 2.1
Aside counts, the figures are reweighted by inverse probability of receiving HbA1c testing.
HbA1c, glycated haemoglobin A1c. 
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impaired fasting glucose (AUROC 0.70, 95% CI 0.67 to 
0.73).
Clinical characteristics of participants meeting diagnostic 
criteria for diabetes
The clinical characteristics of participants who had 
FPG-defined diabetes and for participants who had true/
false-positive results are presented in table 4.
The participants who had FPG-defined diabetes 
(FPG ≥7.0 mmol/L) had a median age of 50 years 
(IQR 41–60) and 65.5% were women. The median 
BMI was 27.9 kg/m2 (IQR 24.2–32.5) and the median 
systolic blood pressure 133.5 mm Hg (IQR 121.5–153). 
The characteristics of true-positive participants (HbA1c 
≥6.5% (140 mg/dL) and FPG ≥7.0 mmol/L) and the 
false-positive participants (HbA1c ≥6.5% (140 mg/dL) 
and FPG <7.0 mmol/L) are also described in table 4.
DIsCussIOn
In a large, multisite sample of adults in Malawi, we found 
that HbA1c is highly predictive of FPG-defined type 2 
diabetes, a relationship which was consistent across 
several subgroups. HbA1c was less predictive for impaired 
fasting glucose. Using a cut-off value of HbA1c6.5% (140 
mg/dL) to detect diabetes, there were demographic and 
clinical differences between true-positive and false-posi-
tive participants.
This analysis is one of the first to compare HbA1c as 
a stand-alone test to detect type 2 diabetes in a black 
Table 2 Sensitivity, specificity and positive and negative likelihood ratios for detecting type 2 diabetes at selected 
glycated haemoglobin A1c (HbA1c) thresholds for participants in Karonga and Lilongwe, Malawi, 2013–2017
HbA1c threshold
Sensitivity (%) Specificity (%)
Positive likelihood 
ratio
Negative likelihood 
ratio% mg/dL SD
6.0 126 +1.0 84.4 86.9 6.5 0.18
6.5* 140 +1.7 78.7 94.0 13.3 0.23
6.6† 143 +1.8 78.3 94.6 14.5 0.23
6.7 146 +2.0 76.5 96.0 19.0 0.25
7.4 166 +3.0 66.3 98.5 43.3 0.34
8.1 186 +4.0 54.8 99.5 117.4 0.45
Figures are reweighted by the inverse probability of receiving HbA1c testing.
*Diagnostic threshold recommended by American Diabetes Association, European Association for the Study of Diabetes, International 
Diabetes Federation and WHO.
†Threshold identified by Youden’s J statistic
SD, standard deviations from the mean HbA1c score among diabetes-negative participants.
Table 3 Overall and stratum-specific area under the receiver operating characteristic (AUROC) curves for detection of type 2 
diabetes with glycated  haemoglobin A1c (HbA1c) among adults in Malawi, 2013–2017
AUROC
(95% CI) Sensitivity (%)* Specificity (%)*
Positive likelihood 
ratio*
Negative 
likelihood ratio*
Overall 0.92 (0.90 to 0.94) 78.7 94.0 13.3 0.23
Site 
  Karonga 0.88 (0.94 to 0.92) 70.2 95.4 15.2 0.31
  Lilongwe 0.94 (0.92 to 0.96) 83.3 92.9 11.7 0.18
Sex 
  Female 0.93 (0.91 to 0.95) 79.1 95.2 16.5 0.22
  Male 0.89 (0.85 to 0.93) 77.6 92.1 9.9 0.24
Body mass index 
  Normal 0.87 (0.83 to 0.92) 70.1 95.1 14.5 0.31
  Overweight 0.93 (0.89 to 0.96) 84.5 91.4 9.9 0.17
  Obese 0.92 (0.89 to 0.95) 80.4 90.6 8.6 0.22
Haemoglobin 
  Normal 0.93 (0.91 to 0.95) 81.4 93.5 12.6 0.20
  Anaemia 0.86 (0.79 to 0.93) 61.5 96.4 17.4 0.40
Figures are reweighted by the inverse probability of receiving HbA1c testing.
*At HbA1c ≥6.5%.
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African population in sub-Saharan Africa, and the first 
from Malawi. In Uganda, Mayega et al found that HbA1c 
had moderate validity (AUROC 0.75) for detecting 
FPG-defined diabetes,22 which was lower than found by 
Hird et al in South Africa (AUROC 0.95). These findings 
from sub-Saharan Africa complement meta-analyses of 
studies in East Asia, Middle East and Europe which show 
that HbA1c is a valid test for detecting diabetes
23–25 across 
different ethnic groups.
There were several notable demographic and clinical 
differences between participants who were true versus 
false positives for FPG-defined diabetes at HbA1c ≥6.5% 
(140 mg/dL). Compared with participants who had 
HbA1c ≥6.5% (140 mg/dL) and FPG <7.0 mmol/L, those 
who had both FPG ≥7.0 and HbA1c ≥6.5% (140 mg/
dL) were more likely to be women, to be older and to 
have higher BMI and blood pressure. These findings 
are consistent with data from the Uganda where the 
AUROC for all participants was 0.75, but was significantly 
higher at 0.90 for overweight participants and 0.98 for 
obese participants. This suggests that HbA1c is particu-
larly useful in in detecting diabetes in individuals with 
insulin resistance or metabolic syndrome (eg, constel-
lation of high BMI, hypertension, dyslipidaemia). In 
contrast, the false-positive group (HbA1c ≥6.5% (140 mg/
dL) and FPG <7.0 mmol/L) lacked features of metabolic 
syndrome. The false-positive group is likely to include 
individuals with isolated postprandial hyperglycaemia, 
rather than fasting hyperglycaemia (perhaps from pancre-
atic deficiency rather than insulin resistance), which 
would require oral glucose tolerance testing (OGTT) to 
demonstrate. Notably, HbA1c has been shown to strongly 
predict OGTT-defined diabetes in South Africa, where 
Hird et al estimated the AUROC at 0.94.26 The clinical 
and demographic differences between true-positive and 
false-positive participants observed here, though inter-
esting, remain descriptive and will require confirmation 
in larger studies.
We found that HbA1c had poor predictive ability for 
detecting impaired fasting glucose. This is consistent 
with other studies in Africa and evidence from a recent 
meta-analysis by Kodama et al.22 25 26 Accordingly, evidence 
strongly suggests that HbA1c may not be appropriate for 
detecting impaired fasting glucose in this population.
Stratum-specific AUROC analysis indicated largely 
consistent values across strata (ie, by sex, site and BMI), 
which is evidence of suitability of HbA1c to detect diabetes 
across a range of groups. However, AUROC values were 
lowest for those with anaemia, which appear to be driven 
by a drop in sensitivity. Different forms of anaemia (eg, 
chronic or acute) affect the integrity and quantity of 
HbA1c-carrying red blood cells, resulting in HbA1c having 
diminished utility as a stand-alone diagnostic tool among 
individuals with anaemia.11 For example, Son et al also 
found that the AUROC for HbA1c to detect OGTT-de-
fined diabetes in South Korea was lower for adults with 
anaemia (0.86 vs 0.88).10 Future research will be required 
to determine how to control anaemia in sub-Saharan 
Africa so that HbA1c testing maintains its validity.
We used FPG rather than OGTT as the reference stan-
dard for diabetes in this analysis. A 2013 meta-analysis 
of 13 cohort studies found that FPG is highly correlated 
to present and to future diabetes,25 though none of the 
studies identified were from sub-Saharan Africa. A 2015 
meta-analysis of diabetes measures found 27 valida-
tion studies of HbA1c using FPG-defined diabetes as the 
Table 4 Clinical characteristics of participants identified as having diabetes by fasting blood glucose and for true/false-
positive participants by glycated haemoglobin A1c (HbA1c) ≥6.5% in Karonga and Lilongwe, Malawi, 2013–2017
Type 2 diabetes positive by 
FPG ≥7.0 mmol/L (IQR)
Type 2 diabetes true positive 
by HbA1c ≥6.5%* (IQR)
Type 2 diabetes 
false positive by 
HbA1c ≥6.5%*† (IQR)
Age, years 50 (41–60) 51 (43–61) 35 (23–51)
Female sex, % 65.6 66.3 51.0
Body mass index, kg/m2 27.9 (24.2–32.5) 28.2 (24.8–32.5) 24.8 (20.9–28.3)
Systolic blood pressure, mm Hg 133.5 (121.5–153) 135 (123–156) 125 (115–136)
Diastolic blood pressure, mm Hg 81.5 (74.5–89.5) 81.5 (75.0–90.5) 74.5 (68.5–82.5)
Total cholesterol, mmol/L 4.9 (4.1–5.7) 5.0 (4.3–5.8) 4.2 (3.5–5.2)
Triglycerides, mmol/L 1.7 (1.2–2.3) 1.8 (1.2–2.5) 0.9 (0.6–1.5)
High-density lipoprotein, mmol/L 1.04 (0.89–1.22) 1.03 (0.88–1.20) 1.15 (0.97–1.29)
Low-density lipoprotein, mmol/L 3.38 (2.69–4.09) 3.52 (2.89–4.22) 2.82 (2.36–3.56)
Haemoglobin, g/dL 13.9 (12.9–14.9) 13.9 (12.9–15.0) 14.2 (13.1–15.1)
HbA1c, % 8.4 (6.9–11.3) 9.6 (7.7–11.8) 6.9 (6.6–7.4)
FPG, mmol/L 9.5 (7.7–14.2) 10.7 (8.3–15.4) 4.8 (4.5–5.1)
Aside counts, figures are weighted by the inverse probability of receiving HbA1c testing.
*Diagnostic threshold recommended by American Diabetes Association, European Association for the Study of Diabetes, WHO and 
International Diabetes Federation.
FPG, fasting plasma glucose.
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diagnostic standard, compared with nine using OGTT.27 
FPG is typically preferred for validation studies due to its 
practical advantages, though it is unclear what proportion 
of individuals with diabetes is missed when FPG testing 
is not paired with OGTT. While FPG is highly correlated 
to present and to future diabetes,24 the frequency of 
OGTT-derived isolated postprandial hyperglycaemia 
or its clinical course is not well defined in sub-Saharan 
Africa, and will require further research. It is worth 
noting that of the two HbA1c validation studies conducted 
among black populations in sub-Saharan Africa, Hird et al 
used both FPG and OGTT as diagnostic standards, with 
consistent results (AUROC 0.95 and 0.94, respectively).26
Not collecting OGTT data constitutes an important 
limitation of our study. In addition, although the overall 
sample size was large and the overall AUROC estimate 
was precise, the subgroups had fewer diabetes cases 
which resulted in our conducting of descriptive rather 
than hypothesis-confirming analysis of subgroup validity. 
Another limitation is that we did not assess the cause or 
type of anaemia, which would have had differential effects 
on HbA1c as well as relevant implications for clinical prac-
tice. A final limitation concerns the decay in glucose levels 
which occurs when blood is stored in fluoride tubes. The 
reduction in variation in glucose levels was independent 
of OGTT result, and so would have resulted our under-
estimating the AUROCs for diabetes and for impaired 
fasting glucose.
Demographic models indicate that sub-Sahara will 
experience a substantial increase in diabetes prevalence 
in the coming years, which will require urgent strategies 
to scale up detection and treatment in order to increase 
access to care. As HbA1c testing is less burdensome to 
patients than FPG and OGTT, it represents a useful option 
for expanding access to diabetes care. This will become 
particularly important as countries in sub-Saharan Africa 
allocate increasing resources to the health sector, and as 
operating costs for the HbA1c test reduce over the next 
few years.
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